Melbourne (Australia) and Indianapolis, IN (U.S.A.) | 28 January 2025 Telix today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and therapeutic radiopharmaceuticals. The acquisition immediately enhances Telix’s presence in the United States (U.S.), with a […]
Read MoreWe are excited to announce that RLS Radiopharmacies, America’s only Joint Commission-accredited nationwide radiopharmacy network distributing PET, SPECT, and therapeutic radiopharmaceuticals, has entered into an agreement to be acquired by Telix Pharmaceuticals Limited (ASX: TLX). Telix is a global radiopharmaceutical company focused on the development and commercialization of therapeutic and […]
Read MoreRadiopharmaceuticals represent a unique class of drug products where compounding and other handling activities include the use of radionuclide generators, the preparation of commercially manufactured radiopharmaceutical kits, the dilution of FDA-approved multi-dose vials, the labeling of human blood products with radionuclides, the preparation of patient-specific radiopharmaceutical doses and more. These […]
Read MoreRLS expands rCDMO capabilities with Eckert & Ziegler’s GalliaPharm® generators for improved patient diagnostics LAKE MARY, FL & BERLIN, GERMANY – April 4, 2024 —RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacynetwork, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement […]
Read MoreRadiopharmaceuticals represent a burgeoning frontier in modern medicine, ushering in a new era of diagnostic and therapeutic potential powered by the principles of nuclear science. While the medical application of radiation dates back over a century, the recent advancements and increasing interest in radiopharmaceuticals have marked the beginning of a […]
Read MoreHAMILTON, ON and LAKE MARY, FL – February 22, 2024 – AtomVie Global Radiopharma Inc. (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), is proud to announce strategic collaborations with RLS Radiopharmacies and UPPI LLC. (UPPI), two industry leaders in radiopharmacy and logistics. This strategic move is poised […]
Read MoreThe nation’s only Joint Commission-accredited radiopharmacy network is bringing life-saving nuclear medicines closer to patients RLS Radiopharmacies, the only Joint Commission-accredited radiopharmacy network in the U.S., announced it is expanding its business operations with the addition of radiopharmaceutical contract development and manufacturing (rCDMO) services. The new offering will enable RLS […]
Read MoreWith increased access to cutting-edge imaging, improved treatment options, greater personalization of treatment, reduced radiation exposure, and potential for future advances, patients can expect to receive more advanced medical care tailored to their specific needs through radiopharmaceuticals. The healthcare field has radically transformed thanks to scientific innovations and technological advancements. […]
Read MoreThese medical isotope-fueled compounds are being used for the diagnosis and treatment of cancer, neurological disorders, and cardiovascular disease.
Read MoreRecent Hires Come as Leading Nuclear Pharmacy Network Continues to Expand Capabilities, Enter New Markets and Partner with Industry Pioneers
Read More